Format

Send to

Choose Destination
Chest. 2014 Aug;146(2):449-475. doi: 10.1378/chest.14-0793.

Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report.

Author information

1
University of Pennsylvania, Philadelphia, PA.
2
CHEST, Glenview, IL. Electronic address: jornelas@chestnet.org.
3
Stanford University and Palo Alto VA Health Care System, Palo Alto, CA.
4
Brown University, Providence, RI.
5
CHEST, Glenview, IL.
6
University of California, San Diego, CA.
7
University of Chicago, Chicago, IL.
8
Ohio State University, Columbus, OH.
9
Columbia University Medical Center, New York, NY.
10
Yale University, New Haven, CT.
11
Johns Hopkins University, Baltimore, MD.
12
Intermountain Medical Center and the University of Utah, Murray, UT.
13
University of Colorado, Denver, CO.

Abstract

OBJECTIVE:

Choices of pharmacologic therapies for pulmonary arterial hypertension (PAH) are ideally guided by high-level evidence. The objective of this guideline is to provide clinicians advice regarding pharmacologic therapy for adult patients with PAH as informed by available evidence.

METHODS:

This guideline was based on systematic reviews of English language evidence published between 1990 and November 2013, identified using the MEDLINE and Cochrane Library databases. The strength of available evidence was graded using the Grades of Recommendations, Assessment, Development, and Evaluation methodology. Guideline recommendations, or consensus statements when available evidence was insufficient to support recommendations, were developed using a modified Delphi technique to achieve consensus.

RESULTS:

Available evidence is limited in its ability to support high-level recommendations. Therefore, we drafted consensus statements to address many clinical questions regarding pharmacotherapy for patients with PAH. A total of 79 recommendations or consensus statements were adopted and graded.

CONCLUSIONS:

Clinical decisions regarding pharmacotherapy for PAH should be guided by high-level recommendations when sufficient evidence is available. Absent higher level evidence, consensus statements based upon available information must be used. Further studies are needed to address the gaps in available knowledge regarding optimal pharmacotherapy for PAH.

PMID:
24937180
PMCID:
PMC4137591
DOI:
10.1378/chest.14-0793
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center